# An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

> **NCT07709533** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 347 (estimated)

## Conditions studied

- Valid MeSH Conditions

## Interventions

- **DRUG:** Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor
- **DRUG:** Retlirafusp alfa / Indole-3-carbinol + Black garlic fermentation extract / Lactobacillus rhamnosus / Placebo + Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor

## Key facts

- **NCT ID:** NCT07709533
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-07
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 347 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709533, "An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*